Abstract
A methotrexate (MTX)-loaded layered double hydroxide (LDH) nanoparticle system was synthesized by intercalating MTX into the interlayer spaces of LDH. In vivo pharmacokinetic study demonstrated that the MTX-LDH hybrid had similar kinetic behaviors as free MTX, showing a rapid decline in the plasma MTX level, with characteristics of a biexponential function. However, the hybrid system remarkably suppressed tumor growth in human osteosarcoma-bearing mice compared to an equivalent amount of free MTX. Using MTX-LDH nanoparticles, a significantly high amount of MTX was delivered to target tumor tissue, whereas a low level was found in normal tissues. Moreover, LDH nanocarriers did not accumulate in any specific tissue nor cause acute toxicity up to the applied dose for the hybrid system. These results suggest that the MTX-LDH nanohybrid system has great potential as an anti-cancer drug with enhanced in vivo anti-tumor activity and bioavailability in target tumor tissue along with reduced side effects.
Keywords: layered double hydroxide, methotrexate, anti-tumor activity, pharmacokinetics, toxicity.
Current Pharmaceutical Design
Title:In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles
Volume: 19 Issue: 41
Author(s): Soo-Jin Choi, Jae-Min Oh, Hae-Eun Chung, Seung-Hee Hong, In-Hoo Kim and Jin-Ho Choy
Affiliation:
Keywords: layered double hydroxide, methotrexate, anti-tumor activity, pharmacokinetics, toxicity.
Abstract: A methotrexate (MTX)-loaded layered double hydroxide (LDH) nanoparticle system was synthesized by intercalating MTX into the interlayer spaces of LDH. In vivo pharmacokinetic study demonstrated that the MTX-LDH hybrid had similar kinetic behaviors as free MTX, showing a rapid decline in the plasma MTX level, with characteristics of a biexponential function. However, the hybrid system remarkably suppressed tumor growth in human osteosarcoma-bearing mice compared to an equivalent amount of free MTX. Using MTX-LDH nanoparticles, a significantly high amount of MTX was delivered to target tumor tissue, whereas a low level was found in normal tissues. Moreover, LDH nanocarriers did not accumulate in any specific tissue nor cause acute toxicity up to the applied dose for the hybrid system. These results suggest that the MTX-LDH nanohybrid system has great potential as an anti-cancer drug with enhanced in vivo anti-tumor activity and bioavailability in target tumor tissue along with reduced side effects.
Export Options
About this article
Cite this article as:
Choi Soo-Jin, Oh Jae-Min, Chung Hae-Eun, Hong Seung-Hee, Kim In-Hoo and Choy Jin-Ho, In Vivo Anticancer Activity of Methotrexate-loaded Layered Double Hydroxide Nanoparticles, Current Pharmaceutical Design 2013; 19 (41) . https://dx.doi.org/10.2174/138161281941131219123718
DOI https://dx.doi.org/10.2174/138161281941131219123718 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cancer and Treatment Modalities
Current Cancer Therapy Reviews Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design Molecular Imaging of Therapeutic Potential of Reporter Probes
Current Drug Targets The Safety and Efficacy of Parathyroid Hormone (PTH) as a Biological Response Modifier for the Enhancement of Bone Regeneration
Current Drug Safety Micro/Nanoparticle Design and Fabrication for Pharmaceutical Drug Preparation and Delivery Applications
Current Drug Therapy The Role of Connexins in Carcinogenesis: Review of Current Knowledge
Current Signal Transduction Therapy Isomers of 4-[<sup>18</sup>F]fluoro-proline: Radiosynthesis, Biological Evaluation and Results in Humans Using PET
Current Radiopharmaceuticals The Emergence of Non-coding RNAs as Versatile and Efficient Therapeutic Tools
Current Gene Therapy Cytotoxic Impact of N-Oleoylethanolamine on Bone Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Deep Penetration of Nanoparticulate Drug Delivery Systems into Tumors: Challenges and Solutions
Current Medicinal Chemistry Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets miR-126 as a Therapeutic Agent for Diabetes Mellitus
Current Pharmaceutical Design Gene Expression Studies in Multiple Sclerosis
Current Genomics Towards Understanding the Roles of Prohibitins, Multi-Functional Regulator Proteins
Current Chemical Biology Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Anti-Angiogenic Therapies for Children with Cancer
Current Cancer Drug Targets Molecular Signaling Pathways and Essential Metabolic Elements in Bone Remodeling: An Implication of Therapeutic Targets for Bone Diseases
Current Drug Targets Therapeutic Potential and Pharmaceutical Applications of <i>Cucurbita</i>
Current Nutrition & Food Science Molecular Mechanisms of PPAR-γ Governing MSC Osteogenic and Adipogenic Differentiation
Current Stem Cell Research & Therapy MicroRNAs and Bone Regeneration
Current Genomics